Association of Antiviral Drugs for the Treatment of COVID-19 With Acute Renal Failure
In Vivo · 2024
DOI: 10.21873/invivo.13637 ↗Kurz gefasst
Fachartikel in der Zeitschrift In Vivo, 2024. Verfasst von Masahiro Kamo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Saga University Hospital, Saga, Japan. Hauptthemen laut MEDLINE: Acute Kidney Injury, Antiviral Agents, COVID-19 Drug Treatment, Adenosine Monophosphate. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Saga University Hospital, Saga, Japan.
- Department of Pharmacy, Saga University Hospital, Saga, Japan sogawari@cc.saga-u.ac.jp.
Zitieren
APA
Kamo, M., Sogawa, R., & Shimanoe, C. (2024). Association of Antiviral Drugs for the Treatment of COVID-19 With Acute Renal Failure. In Vivo. https://doi.org/10.21873/invivo.13637
Vancouver
Kamo M, Sogawa R, Shimanoe C. Association of Antiviral Drugs for the Treatment of COVID-19 With Acute Renal Failure. In Vivo. 2024. doi:10.21873/invivo.13637
BibTeX
@article{Kamo2024,
author = {Kamo, Masahiro and Sogawa, Rintaro and Shimanoe, Chisato},
title = {Association of Antiviral Drugs for the Treatment of COVID-19 With Acute Renal Failure},
journal = {In Vivo},
year = {2024},
doi = {10.21873/invivo.13637}
}
EUVIMED